Quick Answer
Ultragenyx Pharmaceutical Inc. reported R&D Expense of $750.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $750.00M | +7.4% |
| 2024 | $698.00M | +7.7% |
| 2023 | $648.00M | -8.2% |
| 2022 | $705.79M | +42.0% |
| 2021 | $497.15M | +20.6% |
| 2020 | $412.08M | +15.3% |
| 2019 | $357.36M | +21.6% |
| 2018 | $294.00M | +26.9% |
| 2017 | $231.64M | +26.4% |
| 2016 | $183.20M | +59.7% |
| 2015 | $114.74M | +149.6% |
| 2014 | $45.97M | +65.2% |
| 2013 | $27.83M | +120.1% |
| 2012 | $12.64M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $216.21M | +27.1% | +31.2% |
| June 30, 2025 | $164.74M | +2.0% | -0.6% |
| March 31, 2025 | $165.77M | -7.1% | -2.5% |
| September 30, 2024 | $170.11M | +8.2% | +5.3% |
| June 30, 2024 | $161.50M | -2.1% | -9.5% |
| March 31, 2024 | $178.49M | +7.7% | +13.5% |
| September 30, 2023 | $157.25M | -33.7% | -4.7% |
| June 30, 2023 | $164.95M | +6.7% | -0.5% |
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.4% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Ultragenyx Pharmaceutical Inc.’s r&d expense has grown by 5833.1% (from $12.64 million to $750.00 million).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: